Peer-reviewed veterinary case report
Electroporation treatment for oral tumors in dogs with repeated
By Moretti, Giulia et al.·Published in Frontiers in veterinary science·2022·Department of Veterinary Medicine, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Palliative repeated electroporations of oral tumours in dogs: A case series.
- Species:
- dog
Plain-English summary
Nineteen dogs with various types of oral tumors, such as squamous cell carcinoma and malignant melanoma, were treated with a procedure called electrochemotherapy (ECT) that combines electroporation with a chemotherapy drug. This treatment aimed to shrink the tumors and improve the dogs' quality of life. While the overall survival time was low, all dogs showed a good response to the treatment, with noticeable improvements shortly after starting. Importantly, there were minimal side effects, making this a safe option for dogs with non-surgically removable tumors.
People also search for: dog oral tumor treatment · electrochemotherapy for dogs · squamous cell carcinoma in dogs · malignant melanoma in dogs treatment
Abstract
Electrochemotherapy (ECT) is a highly developed treatment for many solid tumours that provides good local control in 80% of neoplasms in dogs. ECT can be used to treat different types of tumours, particularly as an innovative approach for non-resectable masses. As reported in the literature, electroporation-based treatments are safe, simple, fast and cost-effective treatment alternatives for selected oral and maxillofacial tumours not involving the bone in dogs (e.g., small squamous cell carcinoma or malignant melanoma). In this descriptive retrospective paper, the authors describe the outcome of various types of oral tumours treated with ECT as a palliative first line treatment or as a rescue treatment in dogs with local tumour recurrence. Nineteen dogs were included and treated with at least one session of three electroporations coupled with intravenous administration of bleomycin every 21 days. Tumour size, localization, histotype, stage, recurrence, solid tumour response evaluation criteria (RECIST), local toxicity, progression free survival (PFS) and median survival time (MST) were evaluated. The small population did not allow the analysis of the ECT response by comparing different tumour types; further studies with a larger caseload are needed. However, all dogs, despite the low MST, showed a good local response to treatment with a rapid improvement in quality of life from the first ECT application; no side effects attributable to chemotherapy have been detected and toxicity due to the electroporation was minimal and well tolerated in all dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36439338/